Keywords: benefits, erbitux, wt-kras, mcrc, tumors, highlighted, esmo
Benefits of Erbitux in WT-KRAS mCRC tumors highlighted at ESMO
Article | 22 September 2008
The benefits of restricting Merck Serono's epidermal growth factor receptor monoclonal antibody Erbitux (cetuximab) in metastatic colorectal cancer to patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
